Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to “Hold” at Canaccord Genuity GroupBy Publishing TeamJanuary 12, 2023 Oramed Pharmaceuticals (NASDAQ: ORMP – Get Review) was downgraded by equity researchers at Canaccord Genuity Group from a “buy” rating…
HC Wainwright analysts raise earnings estimates for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)By Publishing TeamJanuary 5, 2023 Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) – HC Wainwright raised its fiscal year 2022 EPS estimates for shares of…
